10/12/12 Ulthera, Inc. — a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology — announces the issuance of U.S. Patent No. 8,282,554 this week from the U.S. Patent and Trademark Office (USPTO). The patent, titled “Methods for Treatment of Sweat Glands” relates to the therapeutic use of energy for the treatment of conditions resulting from sweat gland disorders, such as hyperhidrosis. Knobbe Martens has represented Ulthera in its intellectual property matters since 2008.
“This new patent adds a significant asset to the patent portfolio for Ulthera, which has rights to over 100 U.S. and international patents that are issued, published or pending,” said Matthew Likens, Ulthera’s president and CEO. “The groundbreaking advances underlying this patent are a result of many years of collaboration between Ulthera and Guided Therapy Systems, LLC, a global innovator of ultrasound-based technology.”
“It coincides nicely with our recent IDE approval to initiate a pivotal clinical study on axillary (underarm) hyperhidrosis,” Likens continued. “With three percent of the general population profoundly affected by the medical condition and many more who consider themselves ‘sweat-bothered,’ excessive sweating is an area of keen interest to us, and to our core customer base. The potential to treat a medical condition and positively impact a patient’s quality of life is a logical progression for our platform technology.”
Ulthera, Inc. is a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. It is used in a face and neck procedure known as Ultherapy®, which is cleared to lift skin on the brow, neck and under the chin. Founded in 2004 and based in Mesa, Arizona, Ulthera is a privately held company backed by top-tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ultherapy.com.